Trial Profile
Clinical Efficacy and Safety of Delayed Release 6-Mercaptopurine (DR-6MP) for Targeted Ileal Delivery in Patients With Moderately Active Crohn's Disease - Open Label Extension Study [EXTENSION OF 700055062]
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Mercaptopurine (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 14 Mar 2013 Planned number of patients changed to 60.
- 14 Mar 2013 New trial record